OR-1896 | CAS#220246-81-1 | levosimendan metabolite

MedKoo Cat#: 145618 | Name: OR-1896

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OR-1896 is a pharmacologically active metabolite of levosimendan. OR-1896 has pharmacological effects in the endothelium.

Chemical Structure

OR-1896

CAS#220246-81-1

Theoretical Analysis

MedKoo Cat#: 145618

Name: OR-1896

CAS#: 220246-81-1

Chemical Formula: C13H15N3O2

Exact Mass: 245.1200

Molecular Weight: 245.28

Elemental Analysis: C, 63.66; H, 6.16; N, 17.13; O, 13.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

OR-1896; OR1896; OR 1896;

IUPAC/Chemical Name

(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide

InChi Key

GDZXNMWZXLDEKG-MRVPVSSYSA-N

InChi Code

1S/C13H15N3O2/c1-8-7-12(18)15-16-13(8)10-3-5-11(6-4-10)14-9(2)17/h3-6,8H,7H2,1-2H3,(H,14,17)(H,15,18)/t8-/m1/s1

SMILES Code

C[C@@H]1CC(=O)NN=C1C2=CC=C(NC(C)=O)C=C2

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 245.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rayo-Abella LM, Grundig P, Bernhardt MN, Hofmann B, Neumann J, Gergs U. OR-1896 increases force of contraction in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3823-3833. doi: 10.1007/s00210-023-02592-5. Epub 2023 Jun 24. PMID: 37354216; PMCID: PMC10643428. 2: Kipka H, Schaflinger R, Tomasi R, Pogoda K, Mannell H. The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses. Biomedicines. 2023 Mar 16;11(3):918. doi: 10.3390/biomedicines11030918. PMID: 36979897; PMCID: PMC10045601. 3: Kipka H, Liebchen U, Hübner M, Höfner G, Frey O, Wanner KT, Kilger E, Hagl C, Tomasi R, Mannell H. Serum concentrations of levosimendan and its metabolites OR-1855 and OR-1896 in cardiac surgery patients with cardiopulmonary bypass. Front Cardiovasc Med. 2024 Aug 8;11:1406338. doi: 10.3389/fcvm.2024.1406338. PMID: 39175630; PMCID: PMC11338783. 4: Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. doi: 10.1152/ajpheart.01181.2007. Epub 2007 Nov 2. PMID: 17982006. 5: Koskinen M, Puttonen J, Pykäläinen M, Vuorela A, Lotta T. Metabolism of OR-1896, a metabolite of levosimendan, in rats and humans. Xenobiotica. 2008 Feb;38(2):156-70. doi: 10.1080/00498250701744658. PMID: 18197557. 6: Gödény I, Pollesello P, Edes I, Papp Z, Bagi Z. Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo. Pharmacol Rep. 2013;65(5):1304-10. doi: 10.1016/s1734-1140(13)71488-9. PMID: 24399726; PMCID: PMC4016981. 7: Puttonen J, Laine T, Ramela M, Häkkinen S, Zhang W, Pradhan R, Pentikäinen P, Koskinen M. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur J Pharm Sci. 2007 Dec;32(4-5):271-7. doi: 10.1016/j.ejps.2007.08.003. Epub 2007 Aug 10. PMID: 17888637. 8: Ørstavik Ø, Manfra O, Andressen KW, Andersen GØ, Skomedal T, Osnes JB, Levy FO, Krobert KA. The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium. PLoS One. 2015 Mar 4;10(3):e0115547. doi: 10.1371/journal.pone.0115547. PMID: 25738589; PMCID: PMC4349697. 9: Louhelainen M, Merasto S, Finckenberg P, Vahtola E, Kaheinen P, Levijoki J, Mervaala E. Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats. Br J Pharmacol. 2010 May;160(1):142-52. doi: 10.1111/j.1476-5381.2010.00680.x. PMID: 20412071; PMCID: PMC2860214. 10: Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol. 2000 Jul 14;400(1):103-12. doi: 10.1016/s0014-2999(00)00385-x. PMID: 10913591. 11: Segreti JA, Marsh KC, Polakowski JS, Fryer RM. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther. 2008 Apr;325(1):331-40. doi: 10.1124/jpet.107.132530. Epub 2008 Jan 2. PMID: 18171907. 12: Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006 Jul;148(5):696-702. doi: 10.1038/sj.bjp.0706781. Epub 2006 May 22. PMID: 16715115; PMCID: PMC1751872. 13: Takahashi R, Talukder MA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol. 2000 Jul;36(1):118-25. doi: 10.1097/00005344-200007000-00016. PMID: 10892669. 14: Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci. 2004 Nov;23(3):213-22. doi: 10.1016/j.ejps.2004.07.005. PMID: 15489122. 15: Bourgoin P, Lecomte J, Oualha M, Berthomieu L, Pereira T, Davril E, Lamoureux F, Joram N, Chenouard A, Duflot T. Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation. Clin Pharmacokinet. 2023 Feb;62(2):335-348. doi: 10.1007/s40262-022-01199-y. Epub 2023 Jan 11. Erratum in: Clin Pharmacokinet. 2023 Feb;62(2):349. doi: 10.1007/s40262-023-01218-6. PMID: 36631687. 16: Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet. 2007;46(7):535-52. doi: 10.2165/00003088-200746070-00001. PMID: 17596101. 17: Szilágyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol. 2004 Feb 13;486(1):67-74. doi: 10.1016/j.ejphar.2003.12.005. PMID: 14751410. 18: Takahashi R, Endoh M. Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin- loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):440-8. doi: 10.1007/s00210-002-0627-x. Epub 2002 Sep 17. PMID: 12382073. 19: Antoniades C, Antonopoulos AS, Tousoulis D, Bakogiannis C, Stefanadi E, Stefanadis C. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system. Curr Drug Metab. 2009 Feb;10(2):95-103. doi: 10.2174/138920009787522142. PMID: 19275545. 20: Burkhoff D, Rich S, Pollesello P, Papp Z. Levosimendan-induced venodilation is mediated by opening of potassium channels. ESC Heart Fail. 2021 Dec;8(6):4454-4464. doi: 10.1002/ehf2.13669. Epub 2021 Oct 30. PMID: 34716759; PMCID: PMC8712848.